Navigation Links
Therapure Biopharma Inc. opens for business with first client contracts
Date:9/3/2008

TORONTO, Sept. 3 /PRNewswire/ - Therapure Biopharma Inc., a Canadian biopharmaceutical company, announced that it is open for business and has its first contracts with customers in biopharmaceutical development and manufacturing.

Located in Mississauga, Ontario, just 30 minutes from Toronto's Pearson International Airport, Therapure Biopharma provides clients with customized solutions for the development and manufacture of complex biological products. Leveraging its unique and flexible, 130,000 square foot cGMP manufacturing facility, its extensive quality systems, and the dedication of its highly experienced staff, Therapure Biopharma is able to develop effective and innovative solutions to advance therapeutic proteins from the lab to the market.

"We are more than just a contract manufacturing organization (CMO)," said Thomas G. Wellner, President and Chief Executive Officer. "The Company's scientific, manufacturing, and downstream purification expertise, combined with an intimate understanding of advanced biology, complex proteins, and the regulatory requirements for biological drugs, enables us to be a drug development partner with our clients."

Therapure Biopharma offers a wide range of value-added services covering all aspects of protein production so that the scale-up to commercial manufacture will not be a barrier to success. The Company's qualified staff has solved many of the manufacturing challenges facing clients, and the Company will partner with clients to solve their challenges. Many dynamic companies have access to novel, high-value protein-based products that are ready for commercialization but do not have the capabilities to move ahead alone. Therapure Biopharma can help by applying a deep understanding of the market and the business opportunities for protein-based therapeutics.

"We understand the complex regulatory processes for the registration of biological products and have established quality-based cGMP compliant manufacturing processes. We also understand and appreciate the confidential nature of your business and desire a long-term relationship," said Mr. Wellner. "Therapure Biopharma is your one-stop shop for pilot and commercial scale protein/API production, processing, filling, and finishing. We can address your scale-up challenges from bench to commercial scale. Partner with us and we will apply our expertise and proprietary technology to advance your products effectively."

Let Therapure Biopharma be a partner in bringing your biopharmaceutical products to the world. For more information, please visit the company's website at http://www.therapurebio.com.


'/>"/>
SOURCE Therapure Biopharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
2. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
3. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
4. Ondine Biopharma Announces Second Quarter 2008 Financial Results
5. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
8. ARCA biopharma Appoints James Carr as Vice President of Marketing
9. TriCipher is First to Transfer Smart Card Level Security to Federally Approved SAFE-BioPharma(TM) Roaming Credentials
10. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
11. CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):